Fangda represented Kyowa Kirin on the deal. Kyowa Kirin, a global leading R&D company for innovative drugs, has reached a series of asset restructuring arrangements with...
You must be a Standard 1 Year member to access this content.
Fangda advised AnHeart Therapeutics on the deal. Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...
You must be a Standard 1 Year member to access this content.
Fangda represented Kirin Holdings Company on the deal. Kirin Holdings Company executed the sale of its entire 40% stake in its joint venture with China Resources for...
You must be a Standard 1 Year member to access this content.
